Simeprevir 75 mg + TMC647055/ritonavir 450/30 mg | Simeprevir 75 mg + TMC647055/ritonavir 600/50 mg | Simeprevir 75 mg + TMC647055/ritonavir 450/30 mg + JNJ-56914845 30 mg | Simeprevir 75 mg + TMC647055/ritonavir 450/30 mg + JNJ-56914845 60 mg | ||||
---|---|---|---|---|---|---|---|
Panel 1 | Panel 2 | Panel 3 | Panel 4 | ||||
GT1a/with ribavirin (n = 10) | GT1b/with ribavirin (n = 12) | GT1b/without ribavirin (n = 9) | GT1a/with ribavirin (n = 7) | GT1b/without ribavirin (n = 8) | GT1a/b/other (n = 22)a | GT1a/b/other (n = 22)b | |
Any AE, n (%) | 10 (100) | 12 (100) | 7 (78) | 6 (86) | 6 (75) | 20 (91) | 22 (100) |
Worst Grade 1, n (%) | 6 (60) | 7 (58) | 4 (44) | 5 (71) | 3 (38) | 15 (68) | 15 (68) |
Worst Grade 2, n (%) | 4 (40) | 5 (42) | 3 (33) | 1 (14) | 2 (25) | 5 (23) | 6 (27) |
Worst Grade 3, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (13)c | 0 (0) | 1 (5)d |
Worst Grade 4, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Leading to permanent stop of study drugs, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Serious AE, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Death, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |